ArticleJACC. Cardiovascular imaging2024
Prognostic Value of Left Ventricular
Article in JACC. Cardiovascular imaging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Diagnostic Performance of Positron Emission Tomography in the Assessment of Systemic Amyloidosis: A Systematic Review and Meta-Analysis.Reviews in cardiovascular medicine · 2025Pooled it
- Changes in Myocardial Light Chain Amyloid Burden After Plasma Cell Therapy.JACC. Cardiovascular imaging · 2025Trial
- Diagnostic Sensitivity of [18F]-Florbetaben-PET/CT in Detecting Cardiac Involvement in AL Amyloidosis: The Prospective MoRBiDA Study.JACC. Advances · 2026Article
- Imaging Advances in Light Chain Amyloidosis.Diagnostics (Basel, Switzerland) · 2026Review
- Head-to-head comparison ofEuropean journal of nuclear medicine and molecular imaging · 2026Article
- Prognostic parameters and detection of cardiac amyloidosis with hybridEuropean journal of nuclear medicine and molecular imaging · 2026Observational
- Development of Imaging Endpoints for Clinical Trials in AL and ATTR Amyloidosis: Proceedings of the Amyloidosis Forum.JACC. Cardiovascular imaging · 2025Review
- Positron emission tomography in cardiac amyloidosis: current evidence and future directions.Heart failure reviews · 2025Review
- Review
- Cardiac amyloidosis: Innovations in diagnosis and treatment.European heart journal supplements : journal of the European Society of Cardiology · 2025Article
- The Accuracy of Technetium-99 m Pyrophosphate Imaging in Diagnosing Transthyretin Cardiac Amyloidosis and Its Impact on Patient Management.Current cardiology reports · 2025Review
- Prognostic value of left atrial strain in patients with stage II light-chain cardiac amyloidosis receiving cardiac magnetic resonance imaging: a prospective cohort study.Quantitative imaging in medicine and surgery · 2024Article
- Functional Status and Quality of Life in Light-Chain Amyloidosis: Advanced Imaging, Longitudinal Changes, and Outcomes.JACC. Heart failure · 2024Article
- Recent Advances in Positron Emission Tomography Radiotracers to Image Cardiac Amyloidosis.Current cardiology reports · 2024Review
Corrections and comments
- Update of
Authors and funding
15 authors.
Funding
Abstract
backgroundPositron emission tomography/computed tomography (PET/CT) with
objectivesThe authors' aim was to evaluate the prognostic value of LV amyloid burden quantified by
methodsA total of 81 participants with newly diagnosed AL amyloidosis underwent
resultsAmong participants (median age, 61 years; 57% males), 36% experienced MACE, increasing from 7% to 63% across tertiles of LV amyloid burden (P < 0.001). LV amyloid burden was associated with MACE (HR: 1.46; 95% CI: 1.16-1.83; P = 0.001). However, this association became nonsignificant when adjusted for Mayo stage. In mediation analysis, the association between LV amyloid burden and MACE was mediated by NT-proBNP (P < 0.001), a marker of cardiomyocyte stretch and heart failure, and a component of Mayo stage.
conclusionsIn this first study to link cardiac
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.